Erythropoietin drives breast cancer progression by activation of its receptor EPOR

Breast cancer is a leading cause of cancer-related deaths. Anemia is common in breast cancer patients and can be treated with blood transfusions or with recombinant erythropoietin (EPO) to stimulate red blood cell production. Clinical studies have indicated decreased survival in some groups of cance...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Ka Kui, Matchett, Kyle B., Coulter, Jonathan A., Yuen, Hiu-Fung, McCrudden, Cian M., Zhang, Shu-Dong, Irwin, Gareth W., Davidson, Matthew A., Rülicke, Thomas, Schober, Sophie, Hengst, Ludger, Jaekel, Heidelinde, Platt-Higgins, Angela, Rudland, Philip S., Mills, Ken I., Maxwell, Perry, El-Tanani, Mohamed, Lappin, Terence R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5503530/
https://www.ncbi.nlm.nih.gov/pubmed/28418910
http://dx.doi.org/10.18632/oncotarget.16368

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5503530/
https://www.ncbi.nlm.nih.gov/pubmed/28418910
http://dx.doi.org/10.18632/oncotarget.16368

Ejemplares similares